Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Hemispherx (AMEX:HEB) Seeks Rebound: Phase 6 Flu Pandemic

|Includes: Hemispherx Biopharma, Inc (HEB)

With the World Health Organization (WHO) officially declaring the flu a pandemic of phase 6, one company looking to make waves is Hemispherx BioPharma (AMEX:HEB).

Hemispherx has recently been in limbo awaiting FDA decision on the long-awaited treatment for Chronic Fatigue Syndrome (CFS), Ampligen.

Ampligen, also known as poly I:poly C12U, is an experimental immunomodulatory double stranded RNA drug developed by HEMISPHERx Biopharma of Philadelphia, Pennsylvania. Ampligen was first synthesized in the 1970s and has been proposed and tested as a treatment for many illnesses, but primarily chronic fatigue syndrome (ME/CFS) and acquired immunodeficiency syndrome (AIDS).

Summary of articles

Identifying Fact vs. Fiction on Hemispherx’s Ampligen

Hemispherx Ampligen Combats H5N1

Post Approval Hemispherx Ampligen PPS Evaluation

Conference Call - Hemispherx Responds to

Hemispherx Fights Back Against Feuerstein

Conference Call - Hemispherx BioPharma, Inc.

Taking on influenza

Hemispherx has a broad-based technology platform for confronting the potential of an influenza pandemic, which consists of both preventative (vaccine) components as well as experimental therapeutic interventions. Clinical results from trials conducted in Australia are being evaluated and major vaccine initiatives in Japan are being accelerated in collaboration with the Japanese National Institutes of Health and the Japanese Ministry of Health. According to the Japanese National Institute of Infectious Diseases Scientists Identify Hemispherx Biopharma’s Drug Technology as the “Most Promising Mucosal Adjuvant for Influenza.”

StocksHaven Investments believes the phase 6 declaration presents a strong buy signal for Hemispherx BioPharma (AMEX:HEB), within both the short-term and long-term.